Alvotech plans to release Q4 and full year 2025 results on March 18, 2026, with a conference call on March 19.
Quiver AI Summary
Alvotech, a biotechnology company focused on biosimilar medicines, announced it will release its fourth quarter and full year 2025 financial results on March 18, 2026, after U.S. market close. A conference call with a live Q&A session will take place on March 19, 2026, at 08:00 EST. Alvotech aims to be a leader in the biosimilars market, having already launched five approved biosimilars globally and working on nine additional candidates for various diseases. The company has established partnerships to expand its market presence across multiple regions, including the U.S., Europe, and parts of Asia and South America. For further updates, stakeholders can register for the call and visit Alvotech's website.
Potential Positives
- Alvotech is anticipated to release its fourth quarter and full year 2025 financial and operating results, which could provide investors and stakeholders with important insights into the company’s performance.
- The scheduled conference call will allow for direct engagement with management, offering a platform for stakeholders to ask questions and gain clarity on future strategies and developments.
- Alvotech has five biosimilars already approved and marketed, which underscores its established position in the biosimilar market and its capability to deliver products successfully.
- The company has a substantial development pipeline with nine disclosed biosimilar candidates, indicating ongoing innovation and potential growth in various therapeutic areas.
Potential Negatives
- Announcement of upcoming financial results suggests that the company might be under scrutiny for its performance, which could indicate potential weaknesses in financial health.
- The press release does not provide any preliminary financial data or forecasts, leaving investors and analysts uncertain about the company's current standing and future outlook.
- The focus on a specific date for a financial call could imply a lack of immediate positive news, as companies typically release positive results or key updates without delay.
FAQ
When will Alvotech release its Q4 and full year 2025 results?
Alvotech will release its financial results on March 18, 2026, after U.S. markets close.
What time is Alvotech's conference call for Q4 results?
The conference call will be held on March 19, 2026, at 08:00 EST (12:00 GMT, 13:00 CET).
How can I participate in Alvotech's conference call Q&A?
To participate in the Q&A, you need to register for the conference call using the provided registration link.
What biosimilars has Alvotech developed?
Alvotech has developed biosimilars for Humira®, Stelara®, Simponi®, Eylea®, and Prolia®/Xgeva®.
Where can I find more information about Alvotech?
You can visit Alvotech's website at https://www.alvotech.com for more information.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ALVO Hedge Fund Activity
We have seen 28 institutional investors add shares of $ALVO stock to their portfolio, and 37 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HEIGHTS CAPITAL MANAGEMENT, INC removed 1,090,664 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $8,932,538
- OAKTREE CAPITAL MANAGEMENT LP removed 1,030,020 shares (-65.9%) from their portfolio in Q4 2025, for an estimated $5,284,002
- BLACKROCK, INC. added 369,925 shares (+45.9%) to their portfolio in Q4 2025, for an estimated $1,897,715
- MILLENNIUM MANAGEMENT LLC added 337,417 shares (+1707.7%) to their portfolio in Q4 2025, for an estimated $1,730,949
- GILDER GAGNON HOWE & CO LLC removed 195,345 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,599,875
- NORGES BANK removed 180,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $923,400
- VANGUARD GROUP INC added 141,948 shares (+3.3%) to their portfolio in Q4 2025, for an estimated $728,193
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ALVO Analyst Ratings
Wall Street analysts have issued reports on $ALVO in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 11/18/2025
- Morgan Stanley issued a "Overweight" rating on 10/14/2025
To track analyst ratings and price targets for $ALVO, check out Quiver Quantitative's $ALVO forecast page.
$ALVO Price Targets
Multiple analysts have issued price targets for $ALVO recently. We have seen 4 analysts offer price targets for $ALVO in the last 6 months, with a median target of $9.0.
Here are some recent targets:
- Glen Santangelo from Barclays set a target price of $5.0 on 12/09/2025
- Ashwani Verma from UBS set a target price of $10.0 on 11/18/2025
- Niall Alexander from Deutsche Bank set a target price of $8.0 on 11/04/2025
- Thibault Boutherin from Morgan Stanley set a target price of $14.0 on 10/14/2025
Full Release
REYKJAVIK, ICELAND (March 4, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its fourth quarter and full year 2025 financial and operating results on Wednesday, March 18, 2026, after the U.S. markets close.
The Company will also host a conference call with a live Q&A on Thursday, March 19, 2026 at 08:00 EST (12:00 GMT, 13:00 CET).
- To listen to the webcast, register here: Q4 and Full Year 2025 webcast registration
- To participate in the Q&A, register here: Q4 and Full Year 2025 conference call registration
Slides and other material will be made available on Events and Presentations before the call.
For further information, contact:
Media
Benedikt Stefansson
Sarah MacLeod
[email protected]
Investors
Dr. Balaji V Prasad (US)
Patrik Ling (SE)
Benedikt Stefansson (IS)
[email protected]
About Alvotech
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit
https://www.alvotech.com
. None of the information on the Alvotech website shall be deemed part of this press release.
For more information, please visit our investor portal , and our website or follow us on social media on LinkedIn , Facebook , Instagram and YouTube .
